Iron supplementation during treatment with erythropoiesis-stimulating agents for cancer-related anemia

Chemotherapy

Volumn 54, Issue 6, 2008, Pages 417-420

  Schiavetto, Ilaria ^a   Pedrazzoli, Paolo ^a   Basilico, Vera ^a   Siena, Salvatore ^a  

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

Author keywords

Cancer related anemia; Erythropoiesis stimulating agents; Iron supplementation

Indexed keywords

DEXTRAN; ERYTHROPOIETIN; FERRIC GLUCONATE; FERRIC HYDROXIDE SUCROSE; FERROUS GLUCONATE; IRON DEXTRAN; IRON SACCHARATE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; BREAST TUMOR; CHEMOTHERAPY RELATED ANEMIA; CLINICAL TRIAL; COLORECTAL TUMOR; FEMALE GENITAL TRACT TUMOR; FERRITIN BLOOD LEVEL; HUMAN; IRON THERAPY; LUNG TUMOR; PRIORITY JOURNAL; REVIEW;

ANEMIA; DIETARY SUPPLEMENTS; HEMATINICS; HUMANS; IRON; NEOPLASMS;

EID: 52549109865     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000158539     Document Type: Review

References (23)

1. Ludwig H, Fritz E: Anaemia in cancer patients. Semin Oncol 1998;25:2-6.
2. Henry DH: Supplemental iron: a key to optimizing the response of cancer-related anemia to rHuEPO? Oncologist 1998;3:275-278.
3. Bohlius J, Wilson J, Seidenfeld J, et al: Recombinant human erythropoietin and cancer patients: updated meta-analysis of 57 studies including 9,353 patients. J Natl Cancer Inst 2006;98:708-714.
4. Cella D, Dobrez D, Glaspy J: Control of cancer-related anemia with erythropoietic agents: a review of evidence for improved quality of life and clinical outcomes. Ann Oncol 2003;14:511-519.
5. Weiss G, Goodnough LT: Anemia of chronic disease. N Engl J Med 2005;352:1011-1023.
6. Macdougall IC, Tucker B, Thompson J, et al: A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 1996;50:1694-1699.
7. Beguin Y: Prediction of response and other improvements on the limitations of recombinant human erythropoietin therapy in anemic cancer patients. Haematologica 2002;87:1209-1221.
8. Beguin Y: Erytropoietic agents and iron; in Bokemeyer C, Ludwig H (eds): Anaemia in Cancer. ESO Scientific Updates, ed 2. Edinburgh, Elsevier 2005, vol 6, pp 199-220.
9. Andrews NC: Anemia of inflammation: the cytokine-hepcidin link. J Clin Invest 2004;113:1251-1253.
10. Auerbach M: Clinical update: intravenous iron for anaemia. Lancet 2007;369:1502-1504.
11. Chertow GM, Mason PD, Vaage-Nilsen O, Ahlme'n J: Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant 2006;21:378-382.
12. Rizzo JD, Somerfield MR, Hagerty KL, et al: Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. J Clin Oncol 2008;26:132-149.
13. Bokemeyer C, Aapro MS, Courdi A, et al: EORTC guidelines for the use of erythropoietic agents in anaemic patients with cancer: 2006 update. Eur J Cancer 2007;43:258-270.
14. Hedenus M, Birgegard G, Nasman P, et al: Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study. Leukemia 2007;21:627-632.
15. Auerbach M, Ballard H, Trout JR, et al: Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open label, randomized trial. J Clin Oncol 2004;22:1301-1307.
16. Henry DH, Dahl NV, Auerbach M, et al: Intravenous ferric gluconate improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist 2007;12:231-242.
17. Rizzo JD, Lichtin AE, Woolf SH, et al: Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 2002;20:4083-4107.
18. Bastit L, Vandebroek A, Altintas S, et al: Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alfa administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. J Clin Oncol 2008;26:1611-1618.
19. Pedrazzoli P, Farris A, Del Prete S, et al: Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alfa. J Clin Oncol 2008;26:1619-1625.
20. Vansteenkiste J, Pirker R, Massuti B, et al: Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 2007;94:1211-1220.
21. Littlewood TJ, Alikhan R: The use of intravenous iron in patients with cancer-related anaemia. Br J Hematol 2008;141:751-756.
22. Besarab A, Amin N, Ahsan M, et al: Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. J Am Soc Nephrol 2000;1:530-538.
23. Auerbach M: Should intravenous iron be the standard of care in oncology? J Clin Oncol 2008;26:1579-1581.